FDA requires new Phase III trial on Maxim's Ceplene

01/19/2005 | Yahoo!

Maxim Pharmaceuticals reports the FDA is requiring the firm to conduct another Phase III trial on its Ceplene for treating acute myeloid leukemia. The new trial was required because the drug failed a trial last September for treating skin cancer. Maxim has not received word yet from European regulators about whether they also will require a new trial.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care